·More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1 ·DRD is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe.2,3 ·There is an urgent need for earlier detection of DRD [...]
London, Nov. 11, 2024 (Korea Bizwire) – OPEN Health, a preeminent global provider of scientific communications, HEOR and market access, patient engagement, and consulting services, today announced the upcoming presentation of a collection of research supported by its Scientific Buyout Program. The Scientific Buyout Program initiative allows staff members to “buy out” time from their regular duties to engage in important scientific [...]
TEL AVIV, Israel, Nov. 08, 2024 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024. The presentation will begin at 8:30 A.M. Greenwich Mean Time (3.30 A.M. Eastern Time). To access [...]
SPRING, Texas, Nov. 08, 2024 (Korea Bizwire) – Io Therapeutics, Inc., presented results from studies done in breast, colorectal, and prostate cancer models with the company’s newest anti-cancer compound IRX5010, an agonist of the retinoic acid nuclear receptor gamma, which was discovered in the company’s oncology drug program. The presentation titled “RAR Gamma Agonist Compounds [...]
– BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor microenvironment - –In preclinical models, BPT958 induces potent antitumor activity with minimal systemic activation - BASEL, Switzerland and SAN DIEGO, Nov. 08, 2024 (Korea Bizwire) – Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering [...]
First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with enrollment continuing Research Triangle Park, N.C., Nov. 07, 2024 (Korea Bizwire) – Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as LION-101) has received [...]
MedSource Labs Unveils the most intensive remote training tools available to medical professionals, distributors and students. [Minneapolis, Minnesota, Chanhassen], Nov. 07, 2024 (Korea Bizwire) – MedSource Labs and its production partner, Ghost Medical, proudly announce the first training modules designed to improve patient care, comfort and clinician accuracy in peripheral IV Catheters. Through first-of-its-kind digital [...]
WALTHAM, Mass, Nov. 07, 2024 (Korea Bizwire) – Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences: Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, [...]
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023. AUSTEDO® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming [...]
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers VANCOUVER, British Columbia, Nov. 05, 2024 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard [...]